XMT-1660 is under clinical development by Mersana Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XMT-1660’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XMT-1660 overview
XMT-1660 is under development for the treatment of multiple solid tumors such as triple negative breast cancer, ER positive/ HER2 negative breast cancer, endometrial cancer and ovarian cancer. It is administered through intravenous route. The drug candidate comprises of an anti-B7-H4 antibody conjugated to Dolasynthen, with DolaLock Auristatin F-HPA (AF-HPA) anti-tubulin payloads. It is developed based on DolaLock ADC or Dolasynthen technology.
Mersana Therapeutics overview
Mersana Therapeutics (Mersana) is a pharmaceutical company. It develops antibody-drug conjugates (ADC) for the treatment of cancer. The company’s pipeline products XMT-1660, XMT-2056, XMT-2068, and XMT-2175 an ADC that targets sodium-dependent phosphate transport protein NaPi2b utilizing the Dolaflexin platform. Mersana utilizes various technologies including DolaLock Technology, Dolaflexin, Dolasynthen, and Immunosynthen in developing ADCs. Its products also include ASN004 which is in the dose escalation stage. The company develops immunoconjugates to deliver payloads of anti-tumor agents directly to cancerous cells. Its products are used to treat multiple cancer indications including gastric cancer and metastatic breast cancer. Mersana is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of XMT-1660’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
